Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vadadustat DDI Study with Cyclosporine, Probenecid, and Rifampin
NCT03801746Phase 1Completed
- Sponsor
- Akebia Therapeutics
- Start
- Jul 2018
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vadadustat in anemia of chronic kidney disease (CKD-A) (3 arms), sponsored by Akebia Therapeutics. Primary endpoints: Area under plasma concentration-time curve from 0 to last quantifiable concentration up to 10 weeks, Area under plasma concentration-time curve from 0 to infinity up to 10 weeks and 1 more. Started Jul 2018; status: completed.
02
Drugs
vadadustat
03
Conditions
anemia of chronic kidney disease (CKD-A)
Beyond the preview
Go deeper on NCT03801746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03801746.